HiberCell Alternatives & Competitors
12 companies similar to HiberCell — Developing Novel Therapeutics to Prevent Cancer Relapse and Metastasis
Companies similar to HiberCell
Apollomics
We are a biopharmaceutical company committed to the discovery and development of mono- and...
Foster City, United State...
Vuja De Sciences
Vuja De is dedicated to developing cancer metastasis treatments that prevent cancer progre...
ImmunOs Therapeutics AG
Novel human immunomodulatory proteins for cancer and autoimmune diseases with a specific r...
Schlieren, Switzerland
iTeos Therapeutics
Cancer Immunotherapies by Design
Cambridge, United States
Rival Readout
Competing with HiberCell? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
ImmunoGenesis, Inc.
Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mech...
Houston, United States
Aummune
WE ARE ALL UNIQUE SO IS AUMMUNE. The future of personalized therapy for cancer
Israel
Surface Oncology Inc.
#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2...
Cambridge, United States
858 Therapeutics
Discovering innovative small molecule therapeutics for the treatment of cancer
San Diego, United States
Primmune Therapeutics
Engaging Innate Immunity to Cure Cancer
San Diego, United States
Acomhal Research, Inc.
Providing novel and effective therapeutic approaches to prevent tumor recurrence and metas...
Roanoke, United States
Lytix Biopharma
A clinical-stage immuno-oncology company developing proprietary oncolytic drugs as a novel...
Oslo, Norway
Apexigen
Creating Transformative Immunotherapies for Patients with Cancer
San Carlos, United States
About HiberCell
HiberCell, founded in 2019 and headquartered in the United States, is a pioneering force in the Biotechnology and Health Care industries. With a focus on developing novel therapeutics, the company aims to prevent cancer relapse and metastasis. Its slogan, "Developing Novel Therapeutics to Prevent Cancer Relapse and Met...
Development of therapeutic candidates (HC-7366, HC-5404), Clinical-stage research and trials, Exploiting stress-driven vulnerabilities in cancer cells
Cancer patients, Healthcare providers, Biotech investors, Oncologists
Oncology, Therapeutics, Cancer, Metastasis, Clinical Stage, Adaptive Stress Pathways, Anti-tumor Immunity, Product Candidates, Phase 1a Clinical Trials, Cancer Relapse Prevention, New York, Treatment Resistance, Stress Response Kinases, Innate Immune Response
B2B, B2B2C
Licensing, Performance Based, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around HiberCell: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at HiberCell on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Dec 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
